Undergoing surgery is, to be sure, a daunting exercise. Two companies are working together to make it a little easier for children and young teenagers by giving them a pre-op tour in virtual reality.

Reactive oxygen species, or ROS, get a bad rap. The volatile byproducts of chemical reactions with oxygen, they’re well-known markers of inflammation. Their build-up can damage DNA, RNA and proteins in the cell.

Following a shake-up at the top, OncoSec Medical is now reducing its workforce by almost half as it tightens its focus on its lead melanoma trial of its only clinical-stage candidate.

Novo Nordisk added the final piece to the puzzle the Danish drugmaker wanted to complete before submitting its once-weekly insulin icodec to regulators next year.

It’s here: Dexcom is kicking off the international rollout of the newest generation of its real-time continuous glucose monitor, the G7, to help adults and children with diabetes digitally track their blood sugar.

Google Cloud is rolling out a set of tools specifically for digital imaging, designed to make diagnostic data more accessible and interoperable.

Bristol Myers Squibb is looking for a light bulb moment, inking a deal with Autolus Therapeutics that gives the big pharma access to the biotech’s ‘safety switch’ for CAR-T programs.

KalVista Pharmaceuticals’ share price has been cut in half after the company scrapped one of its hereditary angioedema programs in the face of multiple reports of raised enzyme levels.

Pfizer has delivered a split decision on Voyager Therapeutics’ capsids. After spending one year assessing the capsids, the Big Pharma has paid $10 million to take up its option to use the gene therapy technology against a rare neurological disease target but backed out of the cardiovascular part of the deal.

The over-prescription of addictive opioid pain medications has led to untold suffering on account of widespread abuse. Still, the drugs are effective in patients with cancer or who are recovering from surgery, creating a need for a viable alternative or adjunct treatment to reduce reliance on opioids for pain relief.